Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study

被引:182
作者
Glehen, O
Mithieux, F
Osinsky, D
Beaujard, AC
Freyer, G
Guertsch, P
Francois, Y
Peyrat, P
Panteix, G
Vignal, J
Gilly, FN [1 ]
机构
[1] Ctr Hosp Univ Lyon Sud, Dept Surg, F-69495 Pierre Benite, France
[2] Ctr Hosp Univ Lyon Sud, Dept Med Oncol, F-69495 Pierre Benite, France
[3] Ctr Hosp Univ Lyon Sud, Dept Surg, Anesthesiol & Intens Care Unit, F-69495 Pierre Benite, France
[4] Bellinzona Univ Hosp, Dept Surg, Bellinzona, Switzerland
关键词
D O I
10.1200/JCO.2003.06.139
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatasis (PC), a phase II study was carried out from January 1998 to September 2001. Patients and Methods: Fifty-six patients (35 females, mean age 49.3) were included for PC from colorectal cancer (26 patients), ovarian cancer (seven patients), gastric cancer (six patients), peritoneal mesothelioma (five patients), pseudomyxoma peritonei (seven patients), and miscellaneous reasons (five patients). Surgeries were performed mainly on advanced patients (40 patients stages 3 and 4 and 16 patients stages 2 and 1) and were synchronous in 36 patients. All patients underwent surgical resection of their primary tumor with PP and IPCH (with mitomycin C, cisplatinum, or both) with a closed sterile circuit and inflow temperatures ranging from 46degrees to 48degreesC. Three patients were included twice. Results: A macroscopic complete resection was performed in 27 cases. The mortality and morbidity rates were one of 56 and 16 of 56, respectively. The 2-year survival rate was 79.0% for patients with macroscopic complete resection and 44.70% for patients without macroscopic complete resection (P = .001). For the patients included twice, two are alive without evidence of disease, 54 and 47 months after the first procedure. Conclusion: IPCH and PP are able to achieve unexpected long-term survival in patients with bulky PC. However, one must be careful when selecting the patients for such an aggressive treatment, as morbidity rate remains high even for an experienced team. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:799 / 806
页数:8
相关论文
共 39 条
[1]
Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up [J].
Barakat, RR ;
Sabbatini, P ;
Bhaskaran, D ;
Revzin, M ;
Smith, A ;
Venkatraman, E ;
Aghajanian, C ;
Hensley, M ;
Soignet, S ;
Brown, C ;
Soslow, R ;
Markman, M ;
Hoskins, WJ ;
Spriggs, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :694-698
[2]
Beaujard AC, 2000, CANCER-AM CANCER SOC, V88, P2512, DOI 10.1002/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO
[3]
2-J
[4]
BEAUJARD AC, 1999, ANTICANCER RES, V19, P1375
[5]
Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group study [J].
Briasoulis, E ;
Kalofonos, H ;
Bafaloukos, D ;
Samantas, E ;
Fountzilas, G ;
Xiros, N ;
Skarlos, D ;
Christodoulou, C ;
Kosmidis, F ;
Pavlidis, N .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3101-3107
[6]
Cavaliere F, 2000, J SURG ONCOL, V74, P41, DOI 10.1002/1096-9098(200005)74:1<41::AID-JSO10>3.0.CO
[7]
2-R
[8]
CHU DZJ, 1989, CANCER, V63, P364, DOI 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO
[9]
2-V
[10]
Elias D, 2000, Int J Surg Investig, V1, P431